Bloom Science has announced positive topline data from a Phase I clinical trial of BL-001, a potential first-in-class therapeutic the company is developing for Dravet syndrome and amyotrophic lateral sclerosis (ALS). In the trial, BL-001 demonstrated a favourable safety profile and was well tolerated with no serious adverse events (SAEs) across all four dose cohorts. […]